Business Wire

SUZANO

29.2.2024 11:43:27 CET | Business Wire | Press release

Share
Suzano Invests R$18.6 Billion in 2023

Suzano, the world’s largest pulp producer, announces its financial statements for the full fiscal year of 2023.

  • Total investment of R$18.6 billion in 2023, a 14% increase on FY22
  • FY23 Net revenues of R$39.8 billion, a 20% decrease on FY22
  • FY23 Adjusted EBITDA of R$18.3 billion, a 35% decrease on FY22
  • FY23 Operating cash generation of R$11.6 billion, a 49% decrease on FY22
  • FY23 Pulp sales totalled 10.2 million tons, a 4% decrease on FY22
  • FY23 Paper sales totalled 1.3 million tons, a 1% decrease on FY22

Despite the marked decline in global pulp prices over the course of 2023, Suzano has invested over R$18bn to guarantee its future success. It is currently finalising the construction of the Cerrado Project, the world’s largest single-line pulp mill, and has expanded its forestry estate, safeguarding supply and enhancing future competitiveness.

Walter Schalka, CEO of Suzano, said:

“Our investment cycle, including the highest annual investment ever, in 2023, represents the largest in our centennial history with over R$50 billion spent between 2019 and 2023. A further R$16.5 billion will be invested in 2024. In parallel, we have maintained strong cash generation and kept net debt at a sustainable level of US$11.5 billion, reflecting our commitment to strategic growth and financial discipline. We faced a challenging scenario in 2023 and our results demonstrate the company’s resilience to generate value for our stakeholders. With the start-up of Cerrado Project, our structural competitiveness will be more robust in the coming years.”

As the main initiative in Suzano’s current investment plan, the Cerrado Project will be operational by June 2024 and involves total investment of R$22.2 billion. The new mill will add 2.55 million tons of pulp to the company’s current installed capacity of 10.9 million tons of pulp per year.

Other major investments in 2023 include the acquisition of Kimberly-Clark’s tissue assets in Brazil, the expansion of its forests and landholdings base and the modernization of the Jacareí and Aracruz units and port terminals. The company also announced investments to build a tissue paper mill in Aracruz and a project to quadruple the fluff pulp production capacity in Limeira mill. Fluff pulp is the raw material used for manufacturing personal hygiene products, such as baby and adult diapers and sanitary napkins.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228824025/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 09:00:00 CET | Press release

Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav

COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 09:00:00 CET | Press release

The LYCRA Company’s latest innovation minimizes the visible appearance of sweat while delivering moisture management to activewear, ready-to-wear and workwear The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using o

EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 09:00:00 CET | Press release

Eighteen months of EcoOnline primary research highlights seven shifts reshaping safety and sustainability, mirrored in the company’s 2025 customer adoption, product innovation, and growth. EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the

Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release

Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports

Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye